PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV
PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV
PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
Poster Psoriasis<br />
1.19 (0.91, 1.52), respectively; rates for the dose grps combined from yrs1 to 5 were 1.33,<br />
1.03, 0.66, 1.11, and 1.17, respectively. Cumulative rates of non-melanoma skin cancer<br />
(NMSC) per 100PY for UST45mg and UST90mg grps were 0.64 (0.41, 0.95) and 0.44 (0.28,<br />
0.66), respectively; rates for the dose grps combined from yr1 to 5 were 0.94, 0.49, 0.40,<br />
0.42, and 0.16, respectively. Cumulative rates of other malignancies per 100PY for<br />
UST45mg and UST90mg grps were 0.59 (0.37, 0.89) and 0.61 (0.42, 0.87), respectively;<br />
rates for the dose grps combined from yr 1 to 5 were 0.39, 0.97, 0.40, 0.77, and 0.59,<br />
respectively. Investigator-reported MACE rates per 100PY for UST 45mg and UST 90mg<br />
grps were 0.45 (0.26, 0.72) and 0.31 (0.17, 0.50), respectively; rates for the dose grps<br />
combined from yr 1 to 5 were 0.47, 0.24, 0.33, 0.35 and 0.37, respectively. No TB or<br />
serious hypersensitivity reactions were reported. Rates of serious infections,<br />
malignancies, and MACE were stable over time and were consistent with rates<br />
previously described and with observations in the general and/or psoriasis population.<br />
Conclusions: With continuous exposure for up to 5 yrs and approximately 9000 PY<br />
exposure, the long-term safety profile of UST remained stable over time and consistent<br />
with that previously reported after 4yrs of follow-up.<br />
82